These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 38128533)

  • 1. Synthetically mannosylated antigens induce antigen-specific humoral tolerance and reduce anti-drug antibody responses to immunogenic biologics.
    Wallace RP; Refvik KC; Antane JT; Brünggel K; Tremain AC; Raczy MR; Alpar AT; Nguyen M; Solanki A; Slezak AJ; Watkins EA; Lauterbach AL; Cao S; Wilson DS; Hubbell JA
    Cell Rep Med; 2024 Jan; 5(1):101345. PubMed ID: 38128533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthetically mannosylated antigens induce antigen-specific humoral tolerance and reduce anti-drug antibody responses to immunogenic biologics.
    Wallace RP; Refvik KC; Antane JT; Brünggel K; Tremain AC; Raczy MR; Alpar AT; Nguyen M; Solanki A; Slezak AJ; Watkins EA; Lauterbach AL; Cao S; Wilson DS; Hubbell JA
    bioRxiv; 2023 Sep; ():. PubMed ID: 37066302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of ImmTOR Tolerogenic Nanoparticles for the Mitigation of Anti-drug Antibodies.
    Kishimoto TK
    Front Immunol; 2020; 11():969. PubMed ID: 32508839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term humoral unresponsiveness in vivo, induced by treatment with monoclonal antibody against L3T4.
    Goronzy J; Weyand CM; Fathman CG
    J Exp Med; 1986 Sep; 164(3):911-25. PubMed ID: 3091757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity to biologics: mechanisms, prediction and reduction.
    Sethu S; Govindappa K; Alhaidari M; Pirmohamed M; Park K; Sathish J
    Arch Immunol Ther Exp (Warsz); 2012 Oct; 60(5):331-44. PubMed ID: 22930363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization and root cause analysis of immunogenicity to pasotuxizumab (AMG 212), a prostate-specific membrane antigen-targeting bispecific T-cell engager therapy.
    Penny HL; Hainline K; Theoharis N; Wu B; Brandl C; Webhofer C; McComb M; Wittemer-Rump S; Koca G; Stienen S; Bargou RC; Hummel HD; Loidl W; Grüllich C; Eggert T; Tran B; Mytych DT
    Front Immunol; 2023; 14():1261070. PubMed ID: 37942314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-delivery of a CD4 T cell helper epitope via covalent liposome attachment with a surface-arrayed B cell target antigen fosters higher affinity antibody responses.
    Elbahnasawy MA; Donius LR; Reinherz EL; Kim M
    Vaccine; 2018 Oct; 36(41):6191-6201. PubMed ID: 30197285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beyond humanization and de-immunization: tolerization as a method for reducing the immunogenicity of biologics.
    De Groot AS; Terry F; Cousens L; Martin W
    Expert Rev Clin Pharmacol; 2013 Nov; 6(6):651-62. PubMed ID: 24164613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation.
    Jawa V; Cousens LP; Awwad M; Wakshull E; Kropshofer H; De Groot AS
    Clin Immunol; 2013 Dec; 149(3):534-55. PubMed ID: 24263283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Viral Replicative Capacity, Antigen Availability via Hematogenous Spread, and High T
    Eldi P; Chaudhri G; Nutt SL; Newsome TP; Karupiah G
    J Virol; 2019 Mar; 93(6):. PubMed ID: 30626686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation and Induction of Antigen-Specific T Follicular Helper Cells Play a Critical Role in Live-Attenuated Influenza Vaccine-Induced Human Mucosal Anti-influenza Antibody Response.
    Aljurayyan A; Puksuriwong S; Ahmed M; Sharma R; Krishnan M; Sood S; Davies K; Rajashekar D; Leong S; McNamara PS; Gordon S; Zhang Q
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29563292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specificity of humoral and cellular immune response against recombinant particles of nucleocapsid protein of human hepatitis B virus in rabbits.
    Isaguliants MG; Kadoshnikov YP; Kalinina TI; Smirnov VD; Wahren B
    Biochemistry (Mosc); 1998 May; 63(5):551-8. PubMed ID: 9632891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decoration of T-independent antigen with ligands for CD22 and Siglec-G can suppress immunity and induce B cell tolerance in vivo.
    Duong BH; Tian H; Ota T; Completo G; Han S; Vela JL; Ota M; Kubitz M; Bovin N; Paulson JC; Nemazee D
    J Exp Med; 2010 Jan; 207(1):173-87. PubMed ID: 20038598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of potent cellular and humoral immunity against SARS-CoV-2 antigens via conjugation to a polymeric glyco-adjuvant.
    Gray LT; Raczy MM; Briquez PS; Marchell TM; Alpar AT; Wallace RP; Volpatti LR; Sasso MS; Cao S; Nguyen M; Mansurov A; Budina E; Watkins EA; Solanki A; Mitrousis N; Reda JW; Yu SS; Tremain AC; Wang R; Nicolaescu V; Furlong K; Dvorkin S; Manicassamy B; Randall G; Wilson DS; Kwissa M; Swartz MA; Hubbell JA
    Biomaterials; 2021 Nov; 278():121159. PubMed ID: 34634664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell interactions in the immune response in vitro. V. Specific collaboration via complexes of antigen and thymus-derived cell immunoglobulin.
    Feldmann M
    J Exp Med; 1972 Oct; 136(4):737-60. PubMed ID: 4115708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoxia-inducible factors in CD4
    Cho SH; Raybuck AL; Blagih J; Kemboi E; Haase VH; Jones RG; Boothby MR
    Proc Natl Acad Sci U S A; 2019 Apr; 116(18):8975-8984. PubMed ID: 30988188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolerance induction in B lymphocytes but thymus-dependent antigens. T cells may abrogate B-cell tolerance induction by prevent an antibody response.
    Schrader JW
    J Exp Med; 1975 May; 141(5):974-89. PubMed ID: 47898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Immunogenicity of Biologic Therapies.
    Garcês S; Demengeot J
    Curr Probl Dermatol; 2018; 53():37-48. PubMed ID: 29131036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Rapid-Response Humoral Vaccine Platform Exploiting Pre-Existing Non-Cognate Populations of Anti-Vaccine or Anti-Viral CD4+ T Helper Cells to Confirm B Cell Activation.
    Hills T; Jakeman PG; Carlisle RC; Klenerman P; Seymour LW; Cawood R
    PLoS One; 2016; 11(11):e0166383. PubMed ID: 27861512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance.
    Maldonado RA; LaMothe RA; Ferrari JD; Zhang AH; Rossi RJ; Kolte PN; Griset AP; O'Neil C; Altreuter DH; Browning E; Johnston L; Farokhzad OC; Langer R; Scott DW; von Andrian UH; Kishimoto TK
    Proc Natl Acad Sci U S A; 2015 Jan; 112(2):E156-65. PubMed ID: 25548186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.